AMSTERDAM, April 8, 2013 /PRNewswire/ --

Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced a significant content expansion and an improved and enriched user interface for Reaxys, a unique chemistry workflow solution. With this interface and content update Reaxys now supports the entire chemistry workflow resulting in a faster and more efficient research process. Reaxys now encompasses over 16,000 periodicals and has coverage of over 30 million reactions and over 500 million experimentally measured data.

Designed by chemists for chemists, Reaxys enables researchers to advance quickly and confidently through their workflow in order to deliver superior outcomes. An independent survey of 200 users of the product found that the research process was conducted on average 30 percent quicker with Reaxys, when compared to existing alternatives; and related R&D costs were estimated to be reduced by almost 25 percent.

"The pressure on chemists to deliver results is considerable whether they're working in the public or private sector. Like in many other fields, the quantity of data is increasing exponentially. Researchers do not have time to read everything, so they need a solution that helps them to quickly find the right information sources. 95 percent of the top global spenders in pharma use Reaxys because it is flexible enough to accommodate, for example, all the content that researchers need, displayed in one common user interface, ensuring that they don't have to switch from one system to another," said Dr. Jürgen Swienty-Busch, Director of Product Management for Reaxys. "The two most critical things for our customers are innovation and efficiency. By embedding the information they need into their workflow, whether in their E-lab notebook to record experiments or by using an API to display results in a different environment, Reaxys enables researchers to work more efficiently and progress towards their innovation objectives."

"Reaxys' new content and capability expansion of the user interface expands horizons for researchers across all chemistry related domains. Reaxys, in combination with Reaxys Medicinal Chemistry, the domain specific solution, enables users to make more confident decisions about compound selection and synthesis much earlier in the process, improving the likelihood of developing a successful drug and reducing the costs associated with a drug candidate failure in the pre-clinical or clinical development stages," said Meeuwis van Arkel, Vice President Product Development at Elsevier. "Reaxys is interoperable with other innovative solutions which assist researchers across disciplines; this interoperability is vital in promoting organizational efficiency and R&D efficacy."

Reaxys is a key pillar of Elsevier Life Science Solutions, a suite of interoperable, domain-specific, decision support tools which span the discovery and development workflow. Reaxys works with solutions including; ScienceDirect, for immediate full-text access; Scopus, for in-depth bibliometric information; PharmaPendium for a comprehensive view into FDA/EMA approved drugs.

To view Reaxys' new interface and for more information go to: http://www.elsevier.com/reaxys

About Reaxys®

Reaxys® is a workflow solution for research chemists. Offering a wealth of experimentally validated information, Reaxys® combines reaction and substance data in organic, organometallic, inorganic and physical chemistry with synthesis planning. Researchers can get the information they need in a single overview, from source publications carefully selected for their importance and relevance to research chemists. Elsevier continues to engage with the chemistry community to ensure that Reaxys® continues to reflect how chemists think and work. For more information please visit Reaxys.

Reaxys and the Reaxys trademark are owned and protected by Reed Elsevier Properties SA and used under license.

About Elsevier

Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect, Scopus, Reaxys, ClinicalKey and Mosby's Suite, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media contact
Liz Griffioen
Elsevier
+31-20-485-2247
l.griffioen@elsevier.com

SOURCE Elsevier